Mupirocin is a unique topical antibiotic derived from Pseudomonas fluorescens. It is a potent agent primarily used for the treatment of superficial skin infections caused by Gram-positive bacteria, particularly Staphylococcus aureus (including methicillin-resistant S. aureus - MRSA) and Streptococcus pyogenes. Its 2% w/w formulation in a polyethylene glycol base is the standard for topical application, offering high efficacy with minimal systemic absorption.
Adult: Apply a small amount (approx. the size of a pea) to the affected area three times daily (every 8 hours).
Note: 1. Wash and dry the affected area gently. 2. Apply a thin layer of ointment with a cotton swab or gloved finger. 3. Rub in gently until absorbed. 4. May cover with a sterile gauze dressing if desired. 5. Wash hands before and after application. 6. Do not apply to the eyes, nose (unless using nasal formulation), mouth, or inside the vagina. 7. Use for 5-10 days as directed. Do not use for more than 10 days.
Mupirocin inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl-tRNA synthetase (IleS). This enzyme is responsible for charging isoleucine to its cognate tRNA (tRNA^Ile). By binding to the enzyme, mupirocin prevents the formation of isoleucyl-tRNA, thereby halting the incorporation of isoleucine into growing polypeptide chains during protein synthesis.
Pregnancy: Category B: Animal reproduction studies have shown no risk, but no adequate, well-controlled studies in pregnant women. Use only if clearly needed, weighing potential benefits against risks. Systemic absorption is minimal with recommended use.
Driving: No known effect.
| Chloramphenicol (Topical) | Theoretically may antagonize the bactericidal effect of mupirocin; concurrent use not recommended. | Moderate |
| Other Topical Products (Creams, Ointments, Lotions) | Applying other products to the same site may alter the absorption of mupirocin or cause physical/chemical incompatibility. Apply mupirocin first and allow it to absorb fully. | Minor |